---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-190489"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:36:02.868060+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share

## Summary
- Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.
- Underwriters include BofA Securities, Citigroup Global Markets, and Stifel; closing expected July 21, 2023.
- Estimated offering expenses of ~$440,000 excluding underwriting discounts; proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001193125-23-190489
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/0001193125-23-190489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/d467661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-190489
- JSON: https://secwatch.observer/filing/0001193125-23-190489.json
- Plain text: https://secwatch.observer/filing/0001193125-23-190489.txt

## Key facts
- Material Agreements
  Acumen Pharmaceuticals, Inc. entered into Underwriting Agreement with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (effective 2023-07-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters
  - Effective: 2023-07-18
  source text: On July 18, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (the “Underwriters”), relating to a public offering (the “Offering”) of 16,774,193 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $7.75 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/0001193125-23-190489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.